UBS Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.5M | Sell |
78,600
-62,100
| -44% | -$3.4M | ﹤0.01% | 4278 |
|
|
2026
Q1 | $7.95M | Sell |
140,700
-27,900
| -17% | -$1.63M | ﹤0.01% | 3602 |
|
|
2025
Q4 | $10M | Buy |
168,600
+160,400
| +1,956% | +$8.73M | ﹤0.01% | 3281 |
|
|
2025
Q3 | $444K | Sell |
8,200
-17,200
| -68% | -$984K | ﹤0.01% | 6183 |
|
|
2025
Q2 | $1.4M | Buy |
25,400
+13,400
| +112% | +$789K | ﹤0.01% | 5152 |
|
|
2025
Q1 | $848K | Buy |
12,000
+4,500
| +60% | +$303K | ﹤0.01% | 5426 |
|
|
2024
Q4 | $493K | Sell |
7,500
-5,500
| -42% | -$368K | ﹤0.01% | 5848 |
|
|
2024
Q3 | $914K | Buy |
13,000
+5,500
| +73% | +$460K | ﹤0.01% | 4738 |
|
|
2024
Q2 | $617K | Hold |
7,500
| – | – | ﹤0.01% | 4836 |
|
|
2024
Q1 | $655K | Buy |
+7,500
| New | +$671K | ﹤0.01% | 4973 |
|
|
2023
Q3 | – | Sell |
-17,500
| Closed | -$1.52M | – | 9478 |
|
|
2023
Q2 | $1.52M | Buy |
+17,500
| New | +$1.65M | ﹤0.01% | 3817 |
|
|
2022
Q4 | – | Sell |
-68,272
| Closed | -$5.79M | – | 10739 |
|
|
2022
Q3 | $5.79M | Buy |
+68,272
| New | +$6.08M | ﹤0.01% | 2228 |
|
|
2021
Q3 | – | Sell |
-20,000
| Closed | -$1.67M | – | 9548 |
|
|
2021
Q2 | $1.67M | Buy |
+20,000
| New | +$1.59M | ﹤0.01% | 3738 |
|
|
2020
Q4 | – | Sell |
-260
| Closed | -$20K | – | 8392 |
|
|
2020
Q3 | $20K | Sell |
260
-29,740
| -99% | -$3.01M | ﹤0.01% | 6297 |
|
|
2020
Q2 | $3.7M | Buy |
30,000
+4,740
| +19% | +$471K | ﹤0.01% | 2297 |
|
|
2020
Q1 | $2.13M | Sell |
25,260
-6,640
| -21% | -$572K | ﹤0.01% | 2704 |
|
|
2019
Q4 | $2.7M | Buy |
31,900
+6,900
| +28% | +$521K | ﹤0.01% | 3245 |
|
|
2019
Q3 | $1.69M | Buy |
+25,000
| New | +$1.93M | ﹤0.01% | 3468 |
|
|
2019
Q2 | – | Sell |
-250
| Closed | -$22K | – | 7857 |
|
|
2019
Q1 | $22K | Buy |
+250
| New | +$23.2K | ﹤0.01% | 6212 |
|
|
2018
Q3 | – | Sell |
-800
| Closed | -$75K | – | 7980 |
|
|
2018
Q2 | $75K | Buy |
800
+500
| +167% | +$43.8K | ﹤0.01% | 5656 |
|
|
2018
Q1 | $24K | Sell |
300
-14,032
| -98% | -$1.2M | ﹤0.01% | 6273 |
|
|
2017
Q4 | $1.28M | Sell |
14,332
-9,988
| -41% | -$868K | ﹤0.01% | 3569 |
|
|
2017
Q3 | $2.26M | Buy |
+24,320
| New | +$2.15M | ﹤0.01% | 3020 |
|
|
2017
Q2 | – | Sell |
-300
| Closed | -$26K | – | 7676 |
|
|
2017
Q1 | $26K | Sell |
300
-481
| -62% | -$42.8K | ﹤0.01% | 5954 |
|
|
2016
Q4 | $65K | Sell |
781
-99,700
| -99% | -$8.57M | ﹤0.01% | 5617 |
|
|
2016
Q3 | $9.3M | Buy |
100,481
+100,181
| +33,394% | +$9.43M | 0.01% | 1477 |
|
|
2016
Q2 | $23K | Buy |
+300
| New | +$25.5K | ﹤0.01% | 6180 |
|
|
2015
Q3 | – | Sell |
-38,800
| Closed | -$5.31M | – | 8411 |
|
|
2015
Q2 | $5.31M | Buy |
38,800
+19,800
| +104% | +$2.45M | ﹤0.01% | 2010 |
|
|
2015
Q1 | $2.37M | Buy |
19,000
+18,200
| +2,275% | +$1.93M | ﹤0.01% | 2779 |
|
|
2014
Q4 | $72K | Buy |
+800
| New | +$66.5K | ﹤0.01% | 6038 |
|
Other funds holding BMRN
VPC
UBS Group's BMRN Position: Q2 2026 in Review
UBS Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 14% in Q2 2026, selling an estimated $11.5M and leaving 1,286,505 shares worth $73.6M. The position accounts for 0.01% of the portfolio, ranked #1371.
UBS Group first reported a position in BMRN in Q4 2014 and has held it in 47 quarters since. The position peaked at $442M in Q1 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- UBS Group held 1,286,505 shares of BioMarin Pharmaceuticals worth $73.6M as of Q2 2026.
- UBS Group sold 210,347 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $11.5M.
- BioMarin Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q2 2026, its #1371 holding.
- UBS Group first reported a position in BioMarin Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
- UBS Group's BioMarin Pharmaceuticals position peaked at $442M in Q1 2024.
- 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.